Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 18, 2025 72 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR 2026 ESMO TAT Honorary Award Recipient Announced Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage IIIB-C or Stage IV Melanoma Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC MOST POPULAR Opinion: ‘Let’s not be short-sighted – the UK’s medical research charities... September 24, 2020 Imetelstat Shows Durable Transfusion Independence and Disease-Modifying Activity in Heavily Transfused... December 11, 2023 Cancer-Related Fatigue: What People With Cancer and Their Loved Ones Should... August 18, 2020 High-Fat Diet or Diabetes Drug May Enhance Response to Targeted Cancer... August 8, 2018 Load more HOT NEWS Can Topical Drugs Help Prevent Breast Cancer? 120 years of discovery: 10 ways we’ve changed the story for... EMA Recommends Extension of Indications for Durvalumab in the Management of... She Faced Breast Cancer At 16 With Little Help From Doctors....
